Table 2 Heterozygotes and T-allele frequencies in population controls and meningioma patients. Alleles were identified by exon 18 PCR amplification followed by SSCP as described [12].
Groups and number of patients or tumour samples | Heterozygosis frequencya | Group comparison for heterozygotes vs. homozygotesb | T-allele frequencyc | Group comparison for T-allele frequencyb |
|---|---|---|---|---|
A) Control blood from Ecuador N = 149 | 29/149 (0.195) | 31/298 (0.104) | ||
B) Control blood from Spain N = 87 | 15/87 (0.172) | A-B) OR = 1.160 (0.583 – 2.309) P = 0.7313 | 19/174 (0.109) | A-B) OR = 0.878 (0.5175 – 1.734) P = 0.8776 |
C) Patients blood from Spaind N = 22 | 11/22 (0.500) | C-B) OR = 4.800 (1.758 – 13.103) P = 0.0036 | 13/44 (0.295) | C-B) OR = 3.421 (1.531 – 7.646) P = 0.0037 |
D) Meningioma tumours from Spaind,e N = 29 | 2/29 (0.069) | D-B) OR = 0.355 (0.076 – 1.660) P = 0.2327 | 11/49 (0.224) | D-B) OR = 2.357 (1.081 – 5.140) P = 0.0455 |
E) Meningioma tumours from Ecuadorf N = 41 | 30/41 (0.732) | E-A) OR = 11.285 (5.064 – 25.148) P < 0.0001 | 30/82 (0.366) | E-A) OR = 4.969 (2.773 – 8.905) P = 0.0001 |